Lawmakers in France, one of few European countries to still ban medical cannabis use, approved the budget Friday for two years of patient experiments that advocates hope will pave the way for a change in the law.
The National Assembly voted for the tests, already given the green light by France's ANSM medicines regulator, to be paid out of the social security budget for 2020.
"I sincerely hope that the experiments can begin in the first quarter of 2020," junior health minister Christelle Dubos said after the vote.
Olivier Veran, a lawmaker from President Emmanuel Macron's centrist party who proposed the budget inclusion, said the experiments could target some 3,000 sick people in France.
They will seek to determine whether cannabis derivatives can alleviate the symptoms of certain illnesses, and in which doses, he said.
Seventeen other European Union members have already authorised cannabis-based therapies, he added.
The tests will be done at a number of hospitals, with people who have serious conditions such as epilepsy, chronic pain, cancer or involuntary muscle contractions associated with multiple sclerosis.
In July, the ANSM gave the go-ahead for the experiments, which will not see patients getting a prescription for an old-fashioned joint.
For the purposes of the research, the cannabis can be ingested in the form of oil capsules, infusions, or drops.
France, which has one of the highest proportions of recreational drug users in Europe, softened penalties on marijuana use, making in punishable only by an on-the-spot fine of 200 euros.
In June, a group of French economists recommended fully legalising the drug, arguing it said would add billions to state coffers.
But Macron's government has consistently ruled out changing the law to allow people to get legally high.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
